An Observational Study on Sarilumab-exposed Pregnancies

  • STATUS
    Recruiting
  • End date
    Aug 12, 2027
  • participants needed
    300
  • sponsor
    Sanofi
Updated on 19 February 2024

Summary

Primary Objective:

To evaluate the relative risk of major structural birth defects, specifically a pattern of anomalies, in sarilumab-exposed pregnancies compared to disease-matched unexposed pregnancies.

Secondary Objective:

To evaluate the risk for sarilumab-exposure relative to the group of healthy pregnant women, and the effect of exposure on other adverse pregnancy and infants outcomes.

Description

Pregnant women enrolled in the study will participate for the duration of that pregnancy. Those who deliver at least one live born infant and the infants will participate for 1 year after delivery of that infant.

Details
Condition Rheumatoid Arthritis -Exposure During Pregnancy
Age 100 years and younger
Treatment Sarilumab SAR153191 (REGN88)
Clinical Study IdentifierNCT03378219
SponsorSanofi
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Cohort 1: Sarilumab-Exposed Cohort
Currently pregnant, exposed to Kevzara (sarilumab) for approved indication
Cohort 2: Disease-matched Comparison Cohort
Currently pregnant, diagnosed with Kevzara (sarilumab) approved indication
Cohort 3: Non-diseased Comparison Cohort
Currently pregnant, not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara

Exclusion Criteria

First contact the Registry after prenatal diagnosis of any major structural
defect or after pregnancy outcome is known (retrospective data)
Enrolled in this cohort study with a previous pregnancy. Cohort 1: Sarilumab-
Exposed Cohort
Exposed to Kevzara (sarilumab) for an indication other than a currently approved indication
Exposure to another biologic during pregnancy or within 10 weeks prior to the first day of LMP
Exposed to methotrexate, cyclophosphamide, chlorambucil, or mycophenolate mofetil in pregnancy (ie, at any time after the LMP), or leflunomide within two years prior to pregnancy unless a blood level for leflunomide below 0.02 mcg/mL has been documented prior to LMP before the pregnancy
Cohort 2: Disease-matched Comparison Cohort
Exposure to any Kevzara (sarilumab) during pregnancy or within 10 weeks prior to the first day of the LMP
Exposed to methotrexate, cyclophosphamide, chlorambucil, or mycophenolate mofetil in pregnancy (ie, at any time after the LMP), or leflunomide within two years prior to pregnancy unless a blood level for leflunomide below 0.02 mcg/mL has been documented prior to LMP before the pregnancy
Cohort 3: Non-diseased Comparison Cohort
Diagnosed for any serious chronic disease that is thought to adversely impact pregnancy
Exposed to a known human teratogen during pregnancy as confirmed by the OTIS Research Center
The above information is not intended to contain all considerations relevant
to a patient's potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.